- Home
- SCNX vs NNVC Comparison
SCNX vs NNVC Comparison
Compare SCNX & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- NNVC
- Stock Information
- Founded
- SCNX 2010
- NNVC 2005
- Country
- SCNX United States
- NNVC United States
- Employees
- SCNX N/A
- NNVC N/A
- Industry
- SCNX Other Pharmaceuticals
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- NNVC Health Care
- Exchange
- SCNX Nasdaq
- NNVC Nasdaq
- Market Cap
- SCNX 21.2M
- NNVC 22.5M
- IPO Year
- SCNX 2020
- NNVC N/A
- Fundamental
- Price
- SCNX $0.94
- NNVC $1.45
- Analyst Decision
- SCNX
- NNVC
- Analyst Count
- SCNX 0
- NNVC 0
- Target Price
- SCNX N/A
- NNVC N/A
- AVG Volume (30 Days)
- SCNX 298.5K
- NNVC 126.6K
- Earning Date
- SCNX 11-05-2025
- NNVC 11-13-2025
- Dividend Yield
- SCNX N/A
- NNVC N/A
- EPS Growth
- SCNX N/A
- NNVC N/A
- EPS
- SCNX N/A
- NNVC N/A
- Revenue
- SCNX $128,202.00
- NNVC N/A
- Revenue This Year
- SCNX N/A
- NNVC N/A
- Revenue Next Year
- SCNX N/A
- NNVC N/A
- P/E Ratio
- SCNX N/A
- NNVC N/A
- Revenue Growth
- SCNX N/A
- NNVC N/A
- 52 Week Low
- SCNX $0.69
- NNVC $0.94
- 52 Week High
- SCNX $9.55
- NNVC $1.92
- Technical
- Relative Strength Index (RSI)
- SCNX 33.59
- NNVC 48.51
- Support Level
- SCNX $0.83
- NNVC $1.42
- Resistance Level
- SCNX $0.91
- NNVC $1.50
- Average True Range (ATR)
- SCNX 0.06
- NNVC 0.06
- MACD
- SCNX 0.01
- NNVC 0.01
- Stochastic Oscillator
- SCNX 43.05
- NNVC 52.63
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.